Enhancement of Fibrinolysis in Rabbits Exposed to Low and Moderate Levels of Carbon Monoxide Inhibited by Epsilon Amino Caproic Acid

Ekrem V Kalmaz; Larry W Canter; Robert L Coleman; James W Hampton

doi:10.1055/s-0038-1646661

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 1978; 39(01): 109-121
DOI: 10.1055/s-0038-1646661

Original Article

Schattauer GmbH Stuttgart

Enhancement of Fibrinolysis in Rabbits Exposed to Low and Moderate Levels of Carbon Monoxide Inhibited by Epsilon Amino Caproic Acid

Authors

Ekrem V Kalmaz

The Oklahoma Medical Research Foundation, Hematology Research Laboratories, Oklahoma City, Oklahoma 73104, and the NASA – Lyndon B. Johnson Space Center, Biomedical Research Division, DB-7, Houston, Texas 77058, U.S.A.
Larry W Canter

The Oklahoma Medical Research Foundation, Hematology Research Laboratories, Oklahoma City, Oklahoma 73104, and the NASA – Lyndon B. Johnson Space Center, Biomedical Research Division, DB-7, Houston, Texas 77058, U.S.A.
Robert L Coleman

The Oklahoma Medical Research Foundation, Hematology Research Laboratories, Oklahoma City, Oklahoma 73104, and the NASA – Lyndon B. Johnson Space Center, Biomedical Research Division, DB-7, Houston, Texas 77058, U.S.A.
James W Hampton

The Oklahoma Medical Research Foundation, Hematology Research Laboratories, Oklahoma City, Oklahoma 73104, and the NASA – Lyndon B. Johnson Space Center, Biomedical Research Division, DB-7, Houston, Texas 77058, U.S.A.

Abstract

als PDF herunterladen

Summary

The first (control) group of rabbits breathed ambient air whereas the second was exposed to low level carbon monoxide (CO, 50 ppm by volume) for 24 hr continuously for 8 weeks. The third group was exposed to 300 ppm CO for 4 weeks. The fourth group was exposed to 300 ppm CO for the same period of time as the third group but in addition they were also given epsilon amino caproic acid (EACA) orally, and the results compared to Group III. Per cent oxyhemoglobin (HbO₂), per cent hemoglobin (Hb) and per cent carboxyhemoglobin (HbCO) were monitored in all groups. Tests of fibrinolysis were monitored and showed acceleration of the whole blood clot lysis and euglobulin lysis times (ELT). A fibrin plate test confirmed the increased lysis and serum fibrin and/or fibrinogen degradation products (FDP) were elevated in the CO exposed animals. No changes were observed in the same tests in the rabbits exposed to ambient air. The fourth group of animals receiving EACA showed inhibition of lysis and decrease in serum FDP. Alpha-1-antitrypsin and alpha-2-macroglobulin assays in all groups showed no change. Microscopic examination of the large vessels in these test groups showed endothelial damage which indicates a possible source for a plasminogen activator release, or lead to activation of Hageman factor and activated plasma plasminogen proactivator.

PDF (1434 kb)

Referenzen

References
1 Alkjaersig N, Fletcher AP, Sherry S. 1959; Epsilon aminocaproic acid. an inhibitor of plasminogen activation. The Journal of Biological Chemistry 234: 832
2 Astrup P, Kjeldson K, Wanstrup J. 1967; Enhancing influence of carbon monoxide on the development of atheromatosis in cholesterol-fed rabbits. Journal of Altheroseclerosis Research 7: 343
3 Astrup T. 1952. Physiology of fibrinolysis. Koller and Strembi (eds.), Thrombolytic Activity and Related Phenomenon . Schattauer, Stuttgart; New York:
4 Astrup T, Möllertz S. 1952; The fibrin plate method for estimating fibrinolytic activity. Archives of Biochemistry and Biophysics 40: 346
5 Barnhart MI, Cress DC, Henry RL, Riddle JN. 1952; Influence of fibrinogen split products on platelets. Thrombosis et Diathesis Haemorrhagica 17: 78
6 Brackman P. 1952. Fibrinolysis, a Standardized Fibrin Plate and a Fibrinolytic Assay of Plasminogen. Thesis University of Amsterdam, Scheltema and Holkema, N. V
7 Brackman P, Astrup T. 1952. The fibrin plate method and fibrinolytic agents. In: Bang NU, Beller FK, Deutsch E, Mammen EF. (eds.) Thrombosis and Bleeding Disorders. Academic Press; London: 332
8 Bruckner J, Desmond F. 1952; Spectrophotometric methods for the estimation of carbon monoxide hemoglobin in blood. Clinica Chimica Acta 3: 173
9 Deutsch DG, Mertz ET. 1952; Plasminogen. purification from human plasma by affinity chromatography. Science(Washington D. C.) 170: 1095
10 Duckert F, Jung E, Shmerling DE. 1952; A hitherto undescribed congenital haemorrhagic diathesis probably due to fibrin stabilizing factor deficiency. Thrombosis et Diathesis Haemorrhagica 5: 179
11 Fati S, Mole R, Pecora L. 1952; Blood enzyme change during carbon monoxide exposure. Folia Medica 43: 1092
12 Fearnley GR. 1952. Fibrinolysis. Edward Arnold Lts; London:
13 Finlayson JS, Mosesson MW. 1952; Heterogeneity of human fibrinogen. Biochemistry 2: 42
14 Gigli I, Mason JW, Colman RW. Austen 1952; Interactions of plasma kallikrein with CI inhibitor. Journal of Immunology 104: 558
15 Grannis GF. 1952; Plasma fibrinogen. determination normal values physiopathologic shifts and fluctuations. Clinical Chemistry 16: 486
16 Haagen-Smith AJ. 1952; Carbon monoxide levels in city driving. Archives of Environmental Health 12: 548
17 Halperin MH, McFarland RA, Niven JI, Roughton FJW. 1952; The time course of the effect of carbon monoxide on visual thresholds. The Journal of Physiology 146: 583
18 Johnson AJ, Semar M, Newman J. 1952. Estimation of fibrinolytic activity by whole blood eu-globulin clot lysis. In: Tocantins LM, Kazau LA. Blood Coagulation, Hemorrhage and Thrombosis. Grune and Stratton; New York: 465
19 Kollias J, Jordan P. 1952; An improved system for prolonged exposure of small animals to artificial low pressure. Journal of Applied Physiology 20: 742
20 Kowalski E, Budzynski AZ, Kopec M, Latallo ZS, Lipinski B, Wegrzynowicz Z. 1952; Studies on the molecular pathology and pathogenesis of bleeding in servere fibrinolytic states in dogs. Thrombosis et Diathesis Haemorrhagica 12: 69
21 Kwaan HC, LO R. McFadzean 1952; Plasma fibrinolytic activity induced by ischaemia. Clinical Science 15: 245
22 Larrieu MJ. 1952; Action of fibrinogen degradation products and fibrin monomer soluble complexes on platelet aggregation. Scandinavian Journal of Haematology suppl 13: 273
23 Larrieu MJ, Marder VJ, Inceman S. 1952; “Effects of fibrinogen degradation products on platelets and coagulation” in Diffuse Intravascular Clotting. Transactions of the International Committee on Haemostasis and Thrombosis. 1965; Koller F, Streuli JP. 215
24 Latallo ZS, Fletcher AP, Alkjaersig N, Sherry S. 1952; Inhibition of fibrin polymerization by fibrinogen proteolysis products. American Journal of Physiology 202: 681
25 Lee RI, White PD. 1952; A clinical study of the coagulation time in blood. The American Journal of the Medical Sciences 145: 495
26 Mallory FB. 1952. Pathological Techniques. W. B. Saunders; Philadelphia PA: 154
27 Mancini G, Carbonaro AO, Heremans JF. 1952; Immunochemical quantitation of antigens by single radial immunodiffusion. Immunochemistry 2: 235
28 Marder VJ, Shulman NR. 1952; High molecular weight derivatives of human fibrinogen produced by plasmin. II. Mechanism of their anticoagulant activity. Journal of Biological Chemistry 244: 2120
29 Marder VJ, Shulman NR, Carroll WR. 1952; The importance of intermediate degradation products of fibrinogen in fibrinolytic haemorrhage. Transactions of the Association of American Physicians 80: 156
30 Merskey C, Lalezari P, Johnson AH. 1952; A rapid, simple, sensitive method for measuring fibrinolytic split products in human serum. Proceedings of the Society for Experimental Biology and Medicine. 131: 871
31 Mertens BF, McDuffle FC, Bowie EJ W, Owen CA. 1952; Rapid, sensitive method for measuring fibrinogen split products in human serum. Mayo Clinic Proceedings 44: 114
32 Miesch F, Bieth J, Metais P. 1952; The alpha-1-anti trypsin and alpha-2-macroglobulin and protease inhibiting capacity of normal and pathological sera. Clinica Chimica Acta 31: 231
33 Niewiarowski S, Kowalski E. 1952; Anti thrombin formation during proteolysis of fibrinogen. Transactions Vlth Conference of the European Society of Haematology. 560
34 Niewiarowski S, Kowalski E. 1952; Un nouvel anticoagulant derive du fibrinogene. Revue Hematologie 13: 320
35 Rainoff OD, Menzie C. 1952; A new method for the determination of fibrinogen in small samples of plasma. The Journal of Laboratory and Clinical Medicine 37: 316
36 Ratnoff OD, Pensky J, Ogston D, Naff GB. 1952; The inhibition of plasmin, plasma kalli-krein, plasma permeability factor and the C’ lr subcomponent of the first component of complement by the serum C’l esterase inhibitor. Journal of Experimental Medicine 129: 315
37 Rozeno G, Fati S. 1952; Acid and alkaline intra-erythrocytic and serous phosphatases in chronic carbon monoxide poisoning. Folia Medica 42: 1204
38 Sairo O, El-Attar A. 1952; Effect of carbon monoxide on the whole fibrinolytic activity. Industrial Medicine and Surgery 37: 774
39 Triantaphyllopoulos DC. 1952; Anticoagulant effect of incubated fibrinogen. Canadian Journal of Biochemistry 36: 249
40 Kaulla von KN. 1952. Chemistry of thrombosis. Human Fibrinolytic Enzymes. Charles C. Thomas Publisher; Springfield: Illinois 352
41 Kaulla von KN. Swan 1952; Clotting deviation in man during cardiac by-pass fibrinolysis and circulating anti-coagulant. The Journal of Thoracic Surgery 26: 517
42 Wilson PA, Mcnicol GP, Douglas AS. 1952; The effects of fibrinogen degradation products on platelet aggregation. Journal of Clinical Pathology 21: 147
43 Winer BJ. 1952. Statistical Principles in Experimental Design. McGraw-Hill; New York: 20
44 Wintrobe MM, Lee GR, Boggs DR, Bithell TC, Athens JW, Foerster J. 1952. Clinical Hematology. Lea and Febiger; Philadelphia PA: 1061